CASH COW

[BioSpecialist]

MONSTER OPPORTUNITY here on this one trading massive below cash :

CLSD = Market cap $39 Mil // Cash $65 Mil //NDA acceptance IMMINENT & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED Stock trading almost 40% below Cash..lets make money toegther .GL


Clearside BioMedical

Market Cap: $40 Million
Cash: $65 Million
Price: 1.24

Shares Out: 32 Million

https://www.barrons.com/articles/PR-CO-20181219-911604

Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide.

If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.